We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has awarded the company a contract to advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including the Ebola virus.
Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the increasing use of low-molecular-weight heparins, including drugs from Sanofi-Aventis, GlaxoSmithKline, and Pfizer, the market dominance of these therapies in the treatment and prophylaxis of venous thromboembolism will be significantly eroded by novel agents over the 2005-2015 forecast period.
TAP Pharmaceutical Products Inc. announced that it has entered into a co-promotion agreement with Novartis Pharmaceuticals Corporation to co-promote Famvi (famciclovir), an oral antiviral prescription medication.
The FDA announced that the results of two epidemiology studies sponsored by Johnson & Johnson (J&J) will be added to the warning portion of the label for the birth control patch Ortho Evra.
The FDA will now immediately post new drug, abbreviated new drug and biologics license application amendments online to improve electronic access to drug information, the agency says.
Democrats on the Health, Education, Labor and Pensions (HELP) Committee are urging Chairman Mike Enzi (R-Wyo.) to delay the markup of his drug safety bill until there has been a hearing on the bill and time to consider the recommendations in a recent report by the Institute of Medicine (IOM).
Billionaire investor Carl Icahn filed on Thursday to seek shareholder support to remove six of the 12 directors from the board of directors of Imclone Systems Inc.